Evaluation of the effect of Pioglitazone and Vitamin E in Fatty Liver, The effect of Metformin and UDCA on Fatty Liver
Phase 2
Recruiting
- Conditions
- Fatty liver.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT20180404039187N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 158
Inclusion Criteria
Patients aged 18-65 years
Patients who have been diagnosed with non-alcoholic fatty liver based on ultrasound evidence and tests
People with controlled diabetes (HbA1C below 8%)
Exclusion Criteria
People with heart failure (HF) Classes 3 and 4
People with kidney failure (GFR <30)
People with liver cirrhosis
People with bladder cancer
People with Osteoporosis
Pregnant and lactating women
alcohol consumption
People who also use other vitamins containing vitamin E at the same time
People receiving warfarin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Grade ultrasound. Timepoint: At the beginning of the study, 3 months and 6 months later. Method of measurement: Sonography.;Liver Enzymes(AST , ALT). Timepoint: At the beginning of the study, 3 months and 6 months later. Method of measurement: Blood test.
- Secondary Outcome Measures
Name Time Method ipid profile. Timepoint: At the beginning of the study, 3 and 6 months later. Method of measurement: Blood test.